Skip to content

Who answers in China for a drug held by a foreign company

Oak
Two teal feathered dinosaurs, one larger and one smaller, stand on a plinth joined at the ankle by a short brass link.

A company outside China may hold a Chinese drug registration certificate in its own name. The Drug Administration Law then requires it to designate an enterprise legal person in China. That entity performs the obligations of the marketing authorisation holder and bears joint and several liability with the holder.1

Since 1 July 2025 the designation has had its own rules. The entity is called the domestic responsible person (境内责任人), and it must have a quality management system, staff and an office before the drug is first imported and sold.2

Two designations at two moments

Chinese drug law asks a foreign company for a local entity twice, under two instruments.

Registration stageMarketing stage
SourceDrug Registration Measures, Article 9Drug Administration Law, Article 38
Who designatesThe overseas applicantThe overseas holder
What the entity doesHandles drug registration mattersPerforms the holder’s obligations in China
When it must be in placeFor the registration applicationBefore the first import and sale
Liability stated in the textNone stated in Article 9Joint and several with the holder

Article 9 of the Drug Registration Measures requires the applicant to be an enterprise or research institution able to bear legal responsibility. An overseas applicant must designate an enterprise legal person in China to handle registration matters.3

Article 38 of the Drug Administration Law applies once the certificate is held. The holder is the enterprise or research institution that obtained the certificate, and it answers for the drug from non-clinical research to adverse reaction reporting.1

Who may be a domestic responsible person

The National Medical Products Administration issued the Interim Provisions by Announcement No. 137 of 2024, dated 13 November 2024. They took effect on 1 July 2025.2

Article 2 defines the domestic responsible person as the enterprise legal person in China that the overseas holder designates. It performs the holder’s obligations in China and bears joint and several liability with the holder.2 Article 4 sets four conditions, which must all be met.2

  • It is an enterprise legal person established in China.
  • It has a quality management system suited to performing the holder’s obligations.
  • It has the organisation and personnel for those obligations, with dedicated staff who are independently responsible for drug quality management.
  • It has suitable office premises.

Regulations made by the State Council now state the same requirement at a higher level. From 15 May 2026 the designated entity must have quality management and risk control capability. It must also set up a management department and staff it.4

How the designation is made

The designation is reported, and the text describes no approval step. The overseas holder reports the domestic responsible person before the drug is first imported and sold. The report goes through the national drug business application system to the provincial drug regulator where the responsible person is located, with the authorisation materials uploaded.2

Article 6 lists the authorisation materials.2

  • the name, telephone number and email address of the holder’s legal representative or authorised representative, and of its contact person
  • the names and identity document details of the responsible person’s legal representative, head of enterprise and contact person, with its address and organisation chart
  • the original commitment letter on jointly signed obligations, signed by the holder and the responsible person’s legal representative
  • a notarised list of the authorised powers and responsibilities

A reliable electronic signature or seal has the same legal force as a handwritten signature or a stamp.2

Each drug product marketed in China has one domestic responsible person. The same entity may accept designation from different overseas holders and for different imported products.2 Its name, address and contact details are printed in the package insert.2

A change of responsible person is reported within 15 working days after the new authorisation takes effect. The report goes to the provincial regulator where the new responsible person is located. The holder also reports changes of the previous year in its annual report.2

What the responsible person does

Article 11 has the responsible person perform the following obligations together with the overseas holder.2

  • being responsible for drug quality and safety, with a quality assurance system after marketing
  • establishing and operating a drug traceability system
  • establishing and operating the annual reporting system
  • managing changes after marketing and re-registration
  • establishing a pharmacovigilance system and monitoring adverse reactions
  • handling recalls and quality complaints, and reporting them to the provincial regulator
  • submitting reference standards to the National Institutes for Food and Drug Control, and cooperating with sampling and batch release
  • liaising with the overseas holder, and cooperating with inspections of overseas production sites and with investigations
  • other obligations set by laws and regulations

The overseas holder remains responsible for managing the authorisation and any change of it. It must ensure that the responsible person keeps performing while the drug is on the market.2

Supervision

Provincial regulators supervise the responsible persons in their regions and keep a supervision file on each.2 At the first import filing of a drug, the port regulator checks that the package insert carries the responsible person’s details.2

FindingMeasure
The responsible person lacks a condition in Article 4Rectification within a time limit, then suspension of sale and import if the condition is still unmet
The responsible person fails an obligation in Article 11 and the drug may be unsafeWarning, interview, rectification, or suspension of sale, use and import, with the result published
The responsible person breaches the Drug Administration LawPenalty under that law

Liability under the Drug Administration Law

Article 136 applies the law’s provisions on the legal liability of holders to the designated entity. It does so where the entity has failed to perform its obligations under the law.1

The penalties for counterfeit drugs show the scale. Article 116 sets a fine of 15 to 30 times the value of the goods. Where the circumstances are serious and the holder is an overseas enterprise, import of its drugs is prohibited for ten years.1 For substandard drugs, Article 117 sets a fine of 10 to 20 times the value of the goods.1

Article 118 reaches individuals. It covers the legal representative, the principal person in charge, the directly responsible managers and other responsible personnel.1

  • Income received from the unit during the violation is confiscated.
  • A fine of 30 per cent to three times that income is imposed.
  • The person is barred for life from drug production and distribution.
  • The public security authority may impose detention of five to fifteen days.

Article 118 applies to counterfeit drugs, and to substandard drugs where the circumstances are serious.1

Questions people also ask

Can a foreign company hold a drug registration certificate in China?

Article 38 of the Drug Administration Law provides for a marketing authorisation holder that is an overseas enterprise. It must designate an enterprise legal person in China to perform the holder’s obligations.1

When must the domestic responsible person be in place?

The overseas holder reports its domestic responsible person before the drug is first imported and sold.2

Can one company act as responsible person for several products?

The same entity may accept designation from different overseas holders and for different imported products. Each product has one responsible person.2

What happens if the responsible person has no quality system?

The provincial regulator requires rectification within a time limit. Where the condition is still unmet, it suspends sale and import.2

Is the registration agent liable with the applicant?

Article 9 of the Drug Registration Measures requires an overseas applicant to designate an enterprise legal person in China for registration matters. Joint and several liability is stated in Article 38 of the Drug Administration Law, for the entity designated by a holder.13

Footnotes

  1. Drug Administration Law of the People’s Republic of China (revised 2019), Articles 30, 38, 116, 117, 118 and 136. http://www.gd.gov.cn/zwgk/wjk/zcfgk/content/post_2521598.html ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9

  2. National Medical Products Administration, Interim Provisions on the Designation of Domestic Responsible Persons by Overseas Drug Marketing Authorisation Holders, Announcement No. 137 of 2024, Articles 2 to 16 and 18. https://www.gov.cn/zhengce/zhengceku/202411/content_6987154.htm ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11 ↩12 ↩13 ↩14 ↩15 ↩16 ↩17

  3. Measures for the Administration of Drug Registration (State Administration for Market Regulation Order No. 27), Article 9. https://www.gov.cn/zhengce/zhengceku/2020-04/01/content_5498012.htm ↩ ↩2

  4. Regulations for the Implementation of the Drug Administration Law (State Council Order No. 828), Article 25. https://www.gov.cn/gongbao/2026/issue_12546/202602/content_7057461.html ↩

Pothos builds longitudinal molecular profiles of individuals: whole-genome sequencing, single-cell RNA sequencing, and plasma proteomics, delivered as a detailed report, every data file, and stored cells. Build your profile.